TABLE 2.
Virologic response to LPV/r by LPV ATU score in clinical trials of LPV/r
| LPV ATU score | No. of subjects with virologic response/ total no. of subjects (%)
|
||
|---|---|---|---|
| Study 765 (single PI experienced, NNRTI naive; n = 56) | Study 888 (single PI experienced, NNRTI naive; n = 130) | Study 957 (multiple PI experienced, NNRTI naive; n = 50) | |
| 0 | 14/18 (77.8) | 33/46 (71.7) | 3/4 (75.0) |
| 1 | 13/17 (76.5) | 23/31 (74.2) | 10/10 (100.0) |
| 2 | 7/10 (70.0) | 20/26 (76.9) | 6/6 (100.0) |
| 3 | 8/10 (80.0) | 6/12 (50.0) | 6/9 (66.7) |
| 4 | 0/1 (0.0) | 5/8 (62.5) | 7/11 (63.6) |
| 5 | 2/6 (33.3) | 5/6 (83.3) | |
| 6 | 0/1 (0.0) | 1/2 (50.0) | |
| 7 | 0/2 (0.0) | ||
| 0-2 | 34/45 (76) | 76/103 (74) | 19/20 (95) |
| 3-5 | 8/11 (73) | 13/26 (50) | 18/26 (69) |
| 6 or more | 0/1 (0) | 1/4 (25) | |
| Odds ratio per additional mutation (95% CI) | 0.85 (0.50, 1.44) | 0.77 (0.60, 0.98) | 0.60 (0.39, 0.91) |
| P value | 0.544 | 0.034 | 0.017 |